Clindamycin

Bacterial infection is a common clinical disease type. In anti-infective treatment targeting Gram-positive bacteria and anaerobic bacteria, lincosamide antibiotics have always occupied an important position. As a representative variety of this class of drugs, clindamycin binds to the 50S subunit of bacterial ribosomes to inhibit peptide chain elongation, thereby blocking bacterial protein synthesis. Its antibacterial spectrum covers Staphylococcus, Streptococcus, Streptococcus pneumoniae and anaerobic bacteria. It is commonly used clinically for the treatment of respiratory tract infections, skin and soft tissue infections, abdominal infections, pelvic infections and other diseases. It is also an alternative medication option for patients with penicillin allergy, and is widely used in primary medical institutions and specialized diagnosis and treatment.

The global clindamycin market size has maintained stable growth for a long time. In 2023, the overall market size was approximately USD 1.38 billion, with a compound annual growth rate maintained at around 3.2%. China is the core supplier of clindamycin API in the world, with production capacity accounting for more than 85% of the global total production capacity. The domestic market concentration is relatively high, and the combined market share of the top 3 enterprises exceeds 60%. After the implementation of centralized procurement on the preparation side, the clinical usage of clindamycin injections and oral regular-release dosage forms has increased year by year. In the first half of 2024, the procurement volume of clindamycin preparations in domestic medical institutions increased by 7.9% year-on-year, driving the continuous and stable release of API demand.

The original research enterprise of clindamycin is Pfizer, and the original research trade name is Cleocin. The core compound patent expired globally in 1975. At present, the main marketed dosage forms include injections (0.3g, 0.6g), oral capsules (75mg, 150mg, 300mg), as well as topical creams, gels, etc. Among them, the 150mg capsules and 0.6g injections produced by Pfizer have been included in the FDA Reference Listed Drug Catalog, and the domestic Reference Listed Drug Catalog also includes the original research products of corresponding specifications. In terms of domestic API registration, as of now, more than 30 enterprises have obtained A status for their clindamycin API through CDE registration, and there are more than 600 domestic preparation approvals, with sufficient market supply. (Data as of June 2025, please refer to the official CDE website for the latest information)

If relevant impurity reference standards are required in the process of product R&D or quality control, CATO can provide a full set of clindamycin impurity reference standards. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide reliable material basis support for the quality research, stability investigation and other links of APIs and preparations.